课题基金 / 基金详情

Enhancement Training for the Next Generation of Translational Ph.D. Scientists

Enhancement Training for the Next Generation of Translational Ph.D. Scientists
下一代转化博士的强化培训
批准号:
10413926
负责人:
Alisa S. Wolberg
金额:
$19.26万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-01 至 2023-06-30

项目摘要

项目成果

Alisa S. Wolberg的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 在T32-GM 122741的此修订版中,转化医学中的ESTA计划要求五年的支持 培养基础科学博士学生对临床意义的主题进行转化研究,工作 在由科学家、医生-科学家和临床医生组成的多学科团队中,使用最先进的 实验方法和患者来源的资源,以解决临床相关的需求。联合国军司令部 转化医学项目诞生于霍华德休斯医学中心的医学转格拉德计划 该研究所成立至今已超过10年。在这段时间里,翻译中的翻译计划 医学培养了121名博士。来自15个不同的基础科学课程的学生, 医学院,药学院,牙科学院,公共卫生学院, 艺术和科学在转化医学的ESTA计划提供增强培训, 生物医学博士学生导致转化医学证书,这是在授予的时间, 完成博士学位在转化医学的研究生课程的学员完成所需的课程 与人类疾病的发病机制有关,参加每月的方案活动,执行 转化研究,并受益于双导师(与基础科学导师和临床共同导师)。 临床共同导师为每位学员提供量身定制的临床经验,让学生接触 他们所研究的疾病的实际情况,并确定可以 使用基础科学研究方法和途径解决。程序的必要元素 补充个别博士学位的要求。课程,确保完成学位的时间 与典型的博士学位相当。学生.自成立以来,66博士。学生已完成 转化医学证书的要求。2004年的长期目标是 转化医学专业培养博士骨干。研究人员具备必要的知识和技能, 从基本的角度认识,欣赏和解决临床相关的生物学问题 科学我们预计下一代的翻译博士。科学家们会明白 生物学问题具有最大的临床相关性,并将定位于应用新的生物学知识 来创造改善人类健康的工具。
英文摘要
Project Summary/Abstract In this revision of T32-GM122741, the UNC Program in Translational Medicine requests five years of support to train basic science Ph.D. students to perform translational research on topics of clinical significance, working in multidisciplinary teams composed of scientists, physician-scientists, and clinicians, using state-of-the-art experimental approaches and patient-derived resources to address clinically-relevant needs. The UNC Program in Translational Medicine was born out of the Med-into-Grad Initiative of the Howard Hughes Medical Institute and has now existed for >10 years. Over this period of time, the UNC Program in Translational Medicine has trained 121 Ph.D. students from 15 different basic science programs in the UNC School of Medicine, UNC School of Pharmacy, UNC School of Dentistry, UNC School of Public Health, and UNC College of Arts and Sciences. The UNC Program in Translational Medicine provides enhancement training to biomedical Ph.D. students leading to a Certificate in Translational Medicine which is conferred at the time of completion of the Ph.D. Trainees in the UNC Program in Translational Medicine complete required coursework related to the pathogenesis of human disease, participate in monthly programmatic activities, perform translational research, and benefit from dual mentorship (with a basic science mentor and a clinical co-mentor). The clinical co-mentors provide a tailored clinical experience for each trainee, exposing students to the practical realities of the diseases they research and identifying questions of clinical significance that can be addressed using basic science research methods and approaches. The required elements of the program complement requirements of the individual Ph.D. programs, ensuring that the time-to-completion of the degree is comparable to that of the typical Ph.D. student. Since its inception, 66 Ph.D. students have completed the requirements for the Certificate in Translational Medicine. The long-term goal of the UNC Program in Translational Medicine is to train a cadre of Ph.D. researchers with the knowledge and skills necessary to recognize, appreciate, and address clinically-relevant biological problems from the perspective of basic science. We anticipate that this next generation of translational Ph.D. scientists will understand which biological problems are of greatest clinical relevance and will be positioned to apply new biological knowledge to create tools for improved human health.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/cts.12803
发表时间: 2020-11
期刊: Clinical and translational science
影响因子: --
作者: [Ge S, Mendley SR, Gerhart JG, Melloni C, Hornik CP, Sullivan JE, Atz A, Delmore P, Tremoulet A, Harper B, Payne E, Lin S, Erinjeri J, Cohen-Wolkowiez M, Gonzalez D, Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee]
通讯作者: Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee
DOI: 10.1371/journal.pbio.3000956
发表时间: 2021-07
期刊: PLoS biology
影响因子: 9.8
作者: [Brandt PD, Sturzenegger Varvayanis S, Baas T, Bolgioni AF, Alder J, Petrie KA, Dominguez I, Brown AM, Stayart CA, Singh H, Van Wart A, Chow CS, Mathur A, Schreiber BM, Fruman DA, Bowden B, Wiesen CA, Golightly YM, Holmquist CE, Arneman D, Hall JD, Hyman LE, Gould KL, Chalkley R, Brennwald PJ, Layton RL]
通讯作者: Layton RL
DOI: 10.1002/cpt.1990
发表时间: 2021-01
期刊: Clinical pharmacology and therapeutics
影响因子: 6.7
作者: [Salerno SN, Edginton A, Gerhart JG, Laughon MM, Ambalavanan N, Sokol GM, Hornik CD, Stewart D, Mills M, Martz K, Gonzalez D, Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee]
通讯作者: Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee
DOI: 10.1007/s40262-021-01072-4
发表时间: 2022-03
期刊: Clinical pharmacokinetics
影响因子: 4.5
作者: [Gerhart JG, Carreño FO, Edginton AN, Sinha J, Perrin EM, Kumar KR, Rikhi A, Hornik CP, Harris V, Ganguly S, Cohen-Wolkowiez M, Gonzalez D, Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee]
通讯作者: Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee
Enhancement Training for the Next Generation of Translational Ph.D. Scientists
Fibrinogen and Factor XIII in Venous Thrombosis
Fibrinogen and Factor XIII in Venous Thromboembolism
Fibrinogen and Factor XIII in Venous Thromboembolism
海外基金